Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$190.66 -0.2%	$178.01	$140.68 ▼ $192.10	$460.19B	0.4	8.86 million shs	9.46 million shs
MRNA Moderna	$26.83 -2.5%	$25.92	$23.15 ▼ $59.73	$10.75B	2.01	12.07 million shs	10.05 million shs
NVAX Novavax	$8.33 -3.0%	$8.34	$5.01 ▼ $13.34	$1.40B	2.74	4.61 million shs	4.49 million shs
PFE Pfizer	$24.81 -1.7%	$24.83	$20.92 ▼ $29.82	$143.50B	0.55	64.74 million shs	64.53 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	+0.64%	+2.68%	+7.82%	+21.74%	+18.85%
MRNA Moderna	-1.40%	-2.96%	+12.51%	-18.16%	-53.23%
NVAX Novavax	-3.48%	-10.05%	+7.91%	+25.58%	-32.26%
PFE Pfizer	-1.75%	-6.85%	+1.94%	-1.68%	-16.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$190.66 -0.2%	$178.01	$140.68 ▼ $192.10	$460.19B	0.4	8.86 million shs	9.46 million shs
MRNA Moderna	$26.83 -2.5%	$25.92	$23.15 ▼ $59.73	$10.75B	2.01	12.07 million shs	10.05 million shs
NVAX Novavax	$8.33 -3.0%	$8.34	$5.01 ▼ $13.34	$1.40B	2.74	4.61 million shs	4.49 million shs
PFE Pfizer	$24.81 -1.7%	$24.83	$20.92 ▼ $29.82	$143.50B	0.55	64.74 million shs	64.53 million shs

These 7 Stocks Will Be Magnificent in 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	+0.64%	+2.68%	+7.82%	+21.74%	+18.85%
MRNA Moderna	-1.40%	-2.96%	+12.51%	-18.16%	-53.23%
NVAX Novavax	-3.48%	-10.05%	+7.91%	+25.58%	-32.26%
PFE Pfizer	-1.75%	-6.85%	+1.94%	-1.68%	-16.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.73	Moderate Buy	$192.94	1.20% Upside
MRNA Moderna	2.00	Hold	$41.81	55.84% Upside
NVAX Novavax	2.00	Hold	$12.33	48.06% Upside
PFE Pfizer	2.37	Hold	$28.35	14.30% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRNA, JNJ, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/10/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$209.00
10/10/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$33.00 ➝ $32.00
10/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$176.00 ➝ $178.00
10/10/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$31.00 ➝ $32.00
10/9/2025	JNJ Johnson & Johnson	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$186.00 ➝ $212.00
10/8/2025	JNJ Johnson & Johnson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2025	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
10/8/2025	NVAX Novavax	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
10/8/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/7/2025	JNJ Johnson & Johnson	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $213.00
10/6/2025	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$172.00 ➝ $193.00

(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$88.82B	5.17	$13.09 per share	14.56	$29.69 per share	6.42
MRNA Moderna	$3.24B	3.24	N/A	N/A	$28.33 per share	0.95
NVAX Novavax	$682.16M	1.98	N/A	N/A	($3.89) per share	-2.14
PFE Pfizer	$63.63B	2.22	$4.29 per share	5.78	$15.62 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$14.07B	$9.35	19.11	17.22	2.40	25.00%	32.49%	13.00%	10/14/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	0.00	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.28	3.77	104.13	0.11	39.20%	-142.33%	28.65%	11/11/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	7.45	8.19	0.83	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest PFE, MRNA, JNJ, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2025	Q3 2025	MRNA Moderna	-$1.95	N/A	N/A	N/A	$893.29 million	N/A
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
10/14/2025	Q3 2025	JNJ Johnson & Johnson	$2.78	N/A	N/A	N/A	$23.73 billion	N/A
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.20	2.73%	N/A	55.61%	64 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.93%	N/A	91.49%	16 Years

Latest PFE, MRNA, JNJ, and NVAX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/9/2025	PFE Pfizer	quarterly	$0.43	6.82%	11/7/2025	11/7/2025	12/1/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.50	1.01	0.76
MRNA Moderna	N/A	3.93	3.77
NVAX Novavax	5.93	2.36	2.34
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
NVAX Novavax	1.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRNA Moderna	5,800	390.58 million	347.62 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, MRNA, JNJ, and NVAX Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Trading Down 1.7% - What's Next?

4 hours ago | marketbeat.com

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

5 hours ago | marketwatch.com

Sandoz granted tentative approval for generic of Pfizer's Inlyta

October 10 at 11:30 AM | seekingalpha.com

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

October 10 at 10:31 AM | finance.yahoo.com

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

October 10 at 10:15 AM | reuters.com

Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)

October 10 at 10:05 AM | seekingalpha.com

JB Capital LLC Reduces Position in Pfizer Inc. $PFE

October 10 at 7:24 AM | marketbeat.com

Commerzbank Aktiengesellschaft FI Purchases 83,531 Shares of Pfizer Inc. $PFE

October 10 at 6:20 AM | marketbeat.com

Pfizer Inc. $PFE Holdings Boosted by Coerente Capital Management

October 10 at 5:40 AM | marketbeat.com

IFP Advisors Inc Raises Stake in Pfizer Inc. $PFE

October 10 at 5:31 AM | marketbeat.com

Blair William & Co. IL Reduces Stock Holdings in Pfizer Inc. $PFE

October 10 at 5:14 AM | marketbeat.com

Vontobel Holding Ltd. Purchases 14,808 Shares of Pfizer Inc. $PFE

October 10 at 4:51 AM | marketbeat.com

Maryland State Retirement & Pension System Buys 10,986 Shares of Pfizer Inc. $PFE

October 10 at 4:43 AM | marketbeat.com

First Merchants Corp Decreases Stock Holdings in Pfizer Inc. $PFE

October 10 at 4:42 AM | marketbeat.com

Stock Traders Buy High Volume of Call Options on Pfizer (NYSE:PFE)

October 10 at 2:12 AM | americanbankingnews.com

Pfizer (NYSE:PFE) Shares Down 1.8% - What's Next?

October 9 at 12:45 AM | marketbeat.com

Should You Buy Pfizer (PFE) Before a Breakout Begins?

October 9 at 11:31 PM | finance.yahoo.com

Here's Why Pfizer (PFE) Fell More Than Broader Market

October 9 at 6:46 PM | zacks.com

Pfizer Inc. (NYSE:PFE) Plans $0.43 Quarterly Dividend

October 9 at 5:37 PM | marketbeat.com

Pfizer declares $0.43 dividend

October 9 at 5:10 PM | seekingalpha.com

Pfizer Declares Fourth-Quarter 2025 Dividend

October 9 at 5:04 PM | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, MRNA, JNJ, and NVAX Company Descriptions

Johnson & Johnson NYSE:JNJ

$190.66 -0.43 (-0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$191.05 +0.40 (+0.21%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$26.83 -0.70 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$26.52 -0.31 (-1.15%)

As of 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$8.33 -0.26 (-3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$8.25 -0.08 (-0.91%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$24.80 -0.44 (-1.72%)

Closing price 03:59 PM Eastern

Extended Trading

$24.65 -0.15 (-0.62%)

As of 08:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, MRNA, JNJ, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, MRNA, JNJ, and NVAX Earnings

Compare Dividends

Latest PFE, MRNA, JNJ, and NVAX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, MRNA, JNJ, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, MRNA, JNJ, and NVAX Company Descriptions

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools